” The Pfizer of Pot”This tease is from Personal Finance. Any ideas????
This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.
Maybe EMMOFor PYYX
Biomedican
Biomedican to IPO Q1-2 2021
I received the following information from my Subscription to INVESTING DAILY PERSONAL FINANCE. Welcome to the Next “Pfizer of Pot” By JOHN PERSINOS • July 15, 2020
medical marijuana investment: GW Pharmaceuticals (NSDQ: GWPH)
GW Pharmaceuticals also is pursuing the latest innovation in marijuana biotech: synthetic cannabinoids.
GWPH’s team of scientists are seeking new ways to synthesize marijuana, rather than rely on growing the plant naturally. The company now uses the actual plant (harvested by a second party) to extract the oils and compounds it needs. However, by synthesizing vital cannabis elements in the laboratory, the company will be able to save considerable costs and also create medicines that are proprietary and extremely difficult for competitors to replicate.
In addition to its inhouse efforts, GWPH is considering partnerships with companies involved in cannabinoid synthesis. One such potential partner (or acquisition target) is Zynerba Pharmaceuticals (NSDQ: ZYNE). Zynerba is developing transdermal synthetic cannabinoid treatments for both pediatric and adult epilepsies.
GWPH was selling at about $136 a share the beginning of 2021 which I could not afford to buy into, so I bought into ZYNE early January at $3.45 a share and as of today it has crawled up to $3.61. Today GWPH is trading for $138.00 a share.